Try the Demo today!
| SEC Filing | Insider | Company | Trade Date | Transaction | Shares | Avg. Price | Total | % Holdings | Return |
|---|---|---|---|---|---|---|---|---|---|
| 23-Jul-21 4:40 PM View:  | Chiniara Ellen EVP & Chief Legal Officer | Alexion Pharmaceuticals, Inc. (ALXN) | 21-Jul-21 | Disposition | 116,850 | -- | -- | (100%) 116.85K to 0 | |
| 23-Jul-21 4:54 PM View: | Coughlin Christopher J Director | Alexion Pharmaceuticals, Inc. (ALXN) | 21-Jul-21 | Disposition | 42,347 | -- | -- | (100%) 42.35K to 0 | |
| 23-Jul-21 4:52 PM View: | Sarin Aradhana EVP, CFO | Alexion Pharmaceuticals, Inc. (ALXN) | 21-Jul-21 | Disposition | 120,253 | -- | -- | (100%) 120.25K to 0 | |
| 23-Jul-21 4:29 PM View: | Orloff John J EVP, Research & Development | Alexion Pharmaceuticals, Inc. (ALXN) | 21-Jul-21 | Disposition | 146,511 | -- | -- | (100%) 146.51K to 0 | |
| 23-Jul-21 4:34 PM View: | Rummelt Andreas Director | Alexion Pharmaceuticals, Inc. (ALXN) | 21-Jul-21 | Disposition | 28,109 | -- | -- | (100%) 28.11K to 0 | |
| 23-Jul-21 4:37 PM View: | Franchini Indrani Lall EVP, Chief Compliance Officer | Alexion Pharmaceuticals, Inc. (ALXN) | 21-Jul-21 | Disposition | 116,075 | -- | -- | (100%) 116.08K to 0 | |
| 23-Jul-21 4:47 PM View: | Carino Tanisha EVP & CCAO | Alexion Pharmaceuticals, Inc. (ALXN) | 21-Jul-21 | Disposition | 59,226 | -- | -- | (100%) 59.23K to 0 | |
| 23-Jul-21 4:45 PM View: | Mollen John T Director | Alexion Pharmaceuticals, Inc. (ALXN) | 21-Jul-21 | Disposition | 15,336 | -- | -- | (100%) 15.34K to 0 | |
| 23-Jul-21 4:44 PM View: | Brennan David R Director | Alexion Pharmaceuticals, Inc. (ALXN) | 21-Jul-21 | Disposition | 20,873 | -- | -- | (100%) 20.87K to 0 | |
| 23-Jul-21 4:51 PM View: | Friedman Paul A Director | Alexion Pharmaceuticals, Inc. (ALXN) | 21-Jul-21 | Disposition | 12,840 | -- | -- | (100%) 12.84K to 0 | |
| 23-Jul-21 4:36 PM View: | Nader Francois Director | Alexion Pharmaceuticals, Inc. (ALXN) | 21-Jul-21 | Disposition | 13,921 | -- | -- | (100%) 13.92K to 0 | |
| 23-Jul-21 4:48 PM View: | Dunsire Deborah Director | Alexion Pharmaceuticals, Inc. (ALXN) | 21-Jul-21 | Disposition | 14,629 | -- | -- | (100%) 14.63K to 0 | |
| 23-Jul-21 4:49 PM View: | Reinsdorf Judith A Director | Alexion Pharmaceuticals, Inc. (ALXN) | 21-Jul-21 | Disposition | 14,150 | -- | -- | (100%) 14.15K to 0 | |
| 23-Jul-21 4:32 PM View: | Hantson Ludwig CEO Director | Alexion Pharmaceuticals, Inc. (ALXN) | 21-Jul-21 | Disposition | 580,809 | -- | -- | (98%) 589.91K to 9.1K | |
| 23-Jul-21 4:39 PM View: | Bazarko Daniel SVP, Controller, CAO | Alexion Pharmaceuticals, Inc. (ALXN) | 21-Jul-21 | Disposition | 60,207 | -- | -- | (100%) 60.21K to 0 | |
| 23-Jul-21 4:42 PM View: | Goff Brian EVP & Chief Commercial Officer | Alexion Pharmaceuticals, Inc. (ALXN) | 21-Jul-21 | Disposition | 150,832 | -- | -- | (100%) 150.83K to 0 | |
| 16-Jul-21 4:53 PM View: | Franchini Indrani Lall EVP, Chief Compliance Officer | Alexion Pharmaceuticals, Inc. (ALXN) | 14-Jul-21 | Grant | 52,625 | -- | -- | 83% 63.45K to 116.08K | |
| 16-Jul-21 10:00 PM View: | Carino Tanisha EVP & CCAO | Alexion Pharmaceuticals, Inc. (ALXN) | 14-Jul-21 | Grant | 25,813 | -- | -- | 77% 33.41K to 59.23K | |
| 16-Jul-21 4:56 PM View: | Hantson Ludwig CEO Director | Alexion Pharmaceuticals, Inc. (ALXN) | 14-Jul-21 | Grant | 240,741 | -- | -- | 69% 349.17K to 589.91K | |
| 16-Jul-21 4:49 PM View: | Bazarko Daniel SVP, Controller, CAO | Alexion Pharmaceuticals, Inc. (ALXN) | 14-Jul-21 | Grant | 21,708 | -- | -- | 56% 38.5K to 60.21K | |
| 16-Jul-21 10:00 PM View: | Goff Brian EVP & Chief Commercial Officer | Alexion Pharmaceuticals, Inc. (ALXN) | 14-Jul-21 | Grant | 60,144 | -- | -- | 66% 90.69K to 150.83K | |
| 16-Jul-21 4:46 PM View: | Chiniara Ellen EVP & Chief Legal Officer | Alexion Pharmaceuticals, Inc. (ALXN) | 14-Jul-21 | Grant | 54,469 | -- | -- | 87% 62.38K to 116.85K | |
| 16-Jul-21 4:54 PM View: | Sarin Aradhana EVP, CFO | Alexion Pharmaceuticals, Inc. (ALXN) | 14-Jul-21 | Grant | 56,313 | -- | -- | 88% 63.94K to 120.25K | |
| 16-Jul-21 4:48 PM View: | Orloff John J EVP, Research & Development | Alexion Pharmaceuticals, Inc. (ALXN) | 14-Jul-21 | Grant | 60,144 | -- | -- | 70% 86.37K to 146.51K | |
| 09-Jun-21 4:50 PM View: | Franchini Indrani Lall EVP, Chief Compliance Officer | Alexion Pharmaceuticals, Inc. (ALXN) | 08-Jun-21 | Payment of Exercise | 928 | $177.00 | $164,256.00 | (1%) 64.38K to 63.45K | (1%) |
| 09-Jun-21 4:53 PM View: | Orloff John J EVP, Research & Development | Alexion Pharmaceuticals, Inc. (ALXN) | 08-Jun-21 | Payment of Exercise | 1,957 | $177.00 | $346,389.00 | (2%) 88.32K to 86.37K | (1%) |
| 09-Jun-21 4:52 PM View: | Goff Brian EVP & Chief Commercial Officer | Alexion Pharmaceuticals, Inc. (ALXN) | 08-Jun-21 | Payment of Exercise | 1,086 | $177.00 | $192,222.00 | (1%) 91.77K to 90.69K | (1%) |
| 24-May-21 4:29 PM View: | Mollen John T Director | Alexion Pharmaceuticals, Inc. (ALXN) | 20-May-21 | Grant | 2,635 | -- | -- | 21% 12.7K to 15.34K | |
| 24-May-21 4:25 PM View: | Brennan David R Director | Alexion Pharmaceuticals, Inc. (ALXN) | 20-May-21 | Grant | 3,336 | -- | -- | 19% 17.54K to 20.87K | |
| 24-May-21 4:34 PM View: | Friedman Paul A Director | Alexion Pharmaceuticals, Inc. (ALXN) | 20-May-21 | Grant | 2,495 | -- | -- | 24% 10.35K to 12.84K | |
| 24-May-21 4:30 PM View: | Nader Francois Director | Alexion Pharmaceuticals, Inc. (ALXN) | 20-May-21 | Grant | 2,635 | -- | -- | 23% 11.29K to 13.92K | |
| 24-May-21 4:27 PM View: | Dunsire Deborah Director | Alexion Pharmaceuticals, Inc. (ALXN) | 20-May-21 | Grant | 2,495 | -- | -- | 21% 12.13K to 14.63K | |
| 24-May-21 4:32 PM View: | Reinsdorf Judith A Director | Alexion Pharmaceuticals, Inc. (ALXN) | 20-May-21 | Grant | 2,635 | -- | -- | 23% 11.52K to 14.15K | |
| 24-May-21 4:36 PM View: | Coughlin Christopher J Director | Alexion Pharmaceuticals, Inc. (ALXN) | 20-May-21 | Grant | 2,691 | -- | -- | 7% 39.66K to 42.35K | |
| 24-May-21 4:33 PM View: | Rummelt Andreas Director | Alexion Pharmaceuticals, Inc. (ALXN) | 20-May-21 | Grant | 2,495 | -- | -- | 10% 25.61K to 28.11K | |
| 01-Apr-21 7:44 AM View: | Hantson Ludwig CEO Director | Alexion Pharmaceuticals, Inc. (ALXN) | 29-Mar-21 | Payment of Exercise | 2,332 | $154.03 | $359,198.00 | (< 1%) 351.5K to 349.17K | (17%) |
| 02-Mar-21 5:59 PM View: | Carino Tanisha EVP & CCAO | Alexion Pharmaceuticals, Inc. (ALXN) | 01-Mar-21 | Payment of Exercise | 722 | $151.75 | $109,564.00 | (2%) 34.13K to 33.41K | (19%) |
| 02-Mar-21 6:01 PM View: | Hantson Ludwig CEO Director | Alexion Pharmaceuticals, Inc. (ALXN) | 28-Feb-21 | Grant | 83,725 | -- | -- | 31% 267.77K to 351.5K | |
| 02-Mar-21 5:48 PM View: | Bazarko Daniel SVP, Controller, CAO | Alexion Pharmaceuticals, Inc. (ALXN) | 28-Feb-21 | Grant | 7,616 | -- | -- | 25% 30.88K to 38.5K | |
| 02-Mar-21 5:55 PM View: | Goff Brian EVP & Chief Commercial Officer | Alexion Pharmaceuticals, Inc. (ALXN) | 28-Feb-21 | Grant | 24,473 | -- | -- | 36% 67.3K to 91.77K | |
| 02-Mar-21 5:57 PM View: | Chiniara Ellen EVP & Chief Legal Officer | Alexion Pharmaceuticals, Inc. (ALXN) | 28-Feb-21 | Grant | 19,321 | -- | -- | 45% 43.06K to 62.38K | |
| 02-Mar-21 5:52 PM View: | Sarin Aradhana EVP, CFO | Alexion Pharmaceuticals, Inc. (ALXN) | 28-Feb-21 | Grant | 24,473 | -- | -- | 62% 39.47K to 63.94K | |
| 02-Mar-21 5:50 PM View: | Orloff John J EVP, Research & Development | Alexion Pharmaceuticals, Inc. (ALXN) | 28-Feb-21 | Grant | 24,473 | -- | -- | 38% 63.85K to 88.32K | |
| 02-Mar-21 5:54 PM View: | Franchini Indrani Lall EVP, Chief Compliance Officer | Alexion Pharmaceuticals, Inc. (ALXN) | 28-Feb-21 | Grant | 18,033 | -- | -- | 39% 46.34K to 64.38K | |
| 02-Mar-21 5:59 PM View: | Carino Tanisha EVP & CCAO | Alexion Pharmaceuticals, Inc. (ALXN) | 28-Feb-21 | Grant | 18,033 | -- | -- | 112% 16.1K to 34.13K | |
| 21-Dec-20 5:00 PM View: | Bazarko Daniel SVP, Controller, CAO | Alexion Pharmaceuticals, Inc. (ALXN) | 17-Dec-20 | Market Option Sale | 24,066 | $157.70 | $3,795,230.00 | (44%) 54.95K to 30.88K | (14%) |
| 21-Dec-20 5:00 PM View: | Bazarko Daniel SVP, Controller, CAO | Alexion Pharmaceuticals, Inc. (ALXN) | 17-Dec-20 | Option Exercise | 24,066 | $117.04 | $2,816,740.00 | 78% 30.88K to 54.95K | < 1% |
| 18-Dec-20 5:04 PM View: | Sarin Aradhana EVP, CFO | Alexion Pharmaceuticals, Inc. (ALXN) | 16-Dec-20 | Grant | 15,371 | -- | -- | 46% 33.46K to 48.83K | |
| 18-Dec-20 5:06 PM View: | Orloff John J EVP, Research & Development | Alexion Pharmaceuticals, Inc. (ALXN) | 16-Dec-20 | Grant | 40,677 | -- | -- | 91% 44.53K to 85.21K | |
| 18-Dec-20 5:08 PM View: | Franchini Indrani Lall EVP, Chief Compliance Officer | Alexion Pharmaceuticals, Inc. (ALXN) | 16-Dec-20 | Grant | 37,965 | -- | -- | 135% 28.22K to 66.18K |
